Univariate and multivariate analyses of clinical characteristics and prior therapies correlated with freedom from transformation in NLPHL (222 patients)
| Variable . | Univariate analysis P value . | Multivariate analysis P value . | HR (95% CI) . |
|---|---|---|---|
| Clinical characteristics at NLPHL presentation | |||
| Age (<40 vs ≥40) | .3 | ||
| Stage | .2 | ||
| Sex | .3 | ||
| Splenic involvement | <.0001 | .03 | 5.5 (2.0-12.5) |
| B symptoms | .4 | ||
| Prior therapies | |||
| Any prior chemotherapy | .0035 | .04 | 4.3 (1.7-10.5) |
| ABVD | .15 | ||
| CHOP | .2 | ||
| MOPP | .2 | ||
| Rituximab based | .6 |
| Variable . | Univariate analysis P value . | Multivariate analysis P value . | HR (95% CI) . |
|---|---|---|---|
| Clinical characteristics at NLPHL presentation | |||
| Age (<40 vs ≥40) | .3 | ||
| Stage | .2 | ||
| Sex | .3 | ||
| Splenic involvement | <.0001 | .03 | 5.5 (2.0-12.5) |
| B symptoms | .4 | ||
| Prior therapies | |||
| Any prior chemotherapy | .0035 | .04 | 4.3 (1.7-10.5) |
| ABVD | .15 | ||
| CHOP | .2 | ||
| MOPP | .2 | ||
| Rituximab based | .6 |
CI, confidence interval; HR, hazard ratio. Bold text means P value is significant.